CDC73 and pachyonychia congenita: Existing research suggested that mutations in GCM2 could increase the risk of familial or sporadic PHPT (26, 52, 53) and had a tendency for malignancy (26, 53–55), indicating that it might be beneficial for PC and APA patients without CDC73 mutations to screen for GCM2 mutations.